LDS/Medical Tests/Amphetamines/Sympathomimetic Amines, Urine

Amphetamines/Sympathomimetic Amines, Urine

The class of drugs known as "amphetamine type stimulants" act as stimulants for the central nervous system (CNS) and have relatively limited legitimate pharmaceutical uses, including decongestants, attention deficit disorder, and narcolepsy. The drug "amphetamine" was originally synthesized in 1877. Amphetamines were used in the 1930s to treat narcolepsy and depression. Since this time amphetamines have been used to alleviate fatigue, improve performance of simple mental and physical tasks and produce euphoria, which are the main reasons for the continued use and abuse of these compounds.

The word "amphetamine" has been labeled to represent the phenylethylamine class of compounds in general, which have varying degrees of sympathomimetic activity. Besides amphetamine, other drugs that fall into this class of phenylethylamines are methamphetamine, phenmetrazine, methylphenidate, diethylpropion, and propylhexedrine. The increasing illicit use of these drugs has led to their classification as Schedule II controlled substances. The most common abused drug of this class of compounds is methamphetamine. Methamphetamine mode of action is by stimulating the CNS by displacing dopamine from nerve terminal storage vesicles. Many of these compounds can be readily synthesized from pseudoephedrine, which is why purchases of pseudoephedrine-containing compounds are tracked at pharmacies across the United States; each person must show their driver’s license upon purchase and a record is entered into the database of the purchase.

This class of compounds is excreted into the urine in varying amounts, allowing detection by analytical methods such as Immunoassay (IA), Gas Chromatography/Mass spectroscopy (GC/MS), and Liquid Chromatography/Mass Spectroscopy (LC/MS).

Since amphetamines are known as CNS stimulants and their effects are initially considered positive by abusers, they are also one of the more common drugs of abuse. They are psychologically and physiologically addicting. Their side effects include excitement, alertness, euphoria, decreased appetite, and reduced sense of fatigue. At low doses the individual can experience irritability, anxiety, insomnia, blurred vision, increased blood pressure, and heart palpitations. Chronic high dose users may develop a psychosis that can be indistinguishable from acute schizophrenia. Amphetamines are rapidly absorbed from the gastrointestinal tract and widely distributed throughout the body. Amphetamines can remain detectable in urine 3-4 days after ingestion.

  • Therapeutic monitoring in blood
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from an immunoassay (IA) type test indicates only the presence of amphetamine or methamphetamine compound and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC/MS or LC/MS. Additionally, a number of drugs, including Adderall, Dexedrin, Deprenyl, and Didrex are metabolized to amphetamine or methamphetamine, therefore confounding the interpretation in the case of polypharmacy.

Therapeutic concentration in blood: varies based upon drug prescribed
Toxic concentration: varies based upon drug prescribed
Fatal concentration: variable

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are generally used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, whether it is a qualitative method such as IA, or a quantitative method such as GC/MS or LC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below

Immunoassay (IA), Gas Chromatography/Mass Spectroscopy (GC/MS), or Liquid Chromatography/Mass Spectroscopy (LC/MS). The main method of quantification is via LC/MS. This particular method of analysis can be used to detect various compounds such as methamphetamine. This class of compounds can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is generally preferred over acid hydrolysis.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3 days
  • Refrigeration: 14 days
  • Frozen: 14 days
Pharmacogenetic testing, such as genotyping *CYP2D6*, which is partially responsible for metabolism of amphetamine and methamphetamine, may be useful. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Amphetamines/Sympathomimetic DEA Drug Fact Sheet.
  • Levine, Barry (Ed). Amphetamines/Sympathomimetic Amines. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 353-371.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.